#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Coronaviruses ( CoVs ) are single-strand plus RNA viruses , which belong to the order Nidovirales .
2-1	16-29	Coronaviruses	object	new	_	_
2-2	30-31	(	_	_	_	_
2-3	32-36	CoVs	abstract	new	coref	3-1
2-4	37-38	)	_	_	_	_
2-5	39-42	are	_	_	_	_
2-6	43-56	single-strand	_	_	_	_
2-7	57-61	plus	_	_	_	_
2-8	62-65	RNA	object|object[5]	new|new[5]	_	_
2-9	66-73	viruses	object[5]	new[5]	_	_
2-10	74-75	,	_	_	_	_
2-11	76-81	which	_	_	_	_
2-12	82-88	belong	_	_	_	_
2-13	89-91	to	_	_	_	_
2-14	92-95	the	person[7]	new[7]	_	_
2-15	96-101	order	abstract|person[7]	new|new[7]	_	_
2-16	102-113	Nidovirales	person[7]	new[7]	_	_
2-17	114-115	.	_	_	_	_

#Text=CoVs normally infect epithelial cells such as respiratory epithelial cells , intestinal epithelial cells and kidney epithelial cells , which causes respiratory or intestinal tract diseases with various levels of severity .
3-1	116-120	CoVs	abstract	giv	coref	16-22[137_0]
3-2	121-129	normally	_	_	_	_
3-3	130-136	infect	_	_	_	_
3-4	137-147	epithelial	place[9]	new[9]	_	_
3-5	148-153	cells	place[9]	new[9]	_	_
3-6	154-158	such	place[9]	new[9]	_	_
3-7	159-161	as	place[9]	new[9]	_	_
3-8	162-173	respiratory	place[9]|place[11]	new[9]|new[11]	_	_
3-9	174-184	epithelial	place[9]|object|place[11]	new[9]|new|new[11]	coref	3-13
3-10	185-190	cells	place[9]|place[11]	new[9]|new[11]	_	_
3-11	191-192	,	place[9]	new[9]	_	_
3-12	193-203	intestinal	place[9]|place[13]	new[9]|new[13]	_	_
3-13	204-214	epithelial	place[9]|object|place[13]	new[9]|giv|new[13]	coref	3-17
3-14	215-220	cells	place[9]|place[13]	new[9]|new[13]	_	_
3-15	221-224	and	place[9]	new[9]	_	_
3-16	225-231	kidney	place[9]|place[15]	new[9]|new[15]	coref	16-36[140_15]
3-17	232-242	epithelial	place[9]|object|place[15]	new[9]|giv|new[15]	_	_
3-18	243-248	cells	place[9]|place[15]	new[9]|new[15]	_	_
3-19	249-250	,	_	_	_	_
3-20	251-256	which	_	_	_	_
3-21	257-263	causes	_	_	_	_
3-22	264-275	respiratory	abstract[17]	new[17]	_	_
3-23	276-278	or	abstract[17]	new[17]	_	_
3-24	279-289	intestinal	abstract[17]	new[17]	_	_
3-25	290-295	tract	object|abstract[17]	new|new[17]	_	_
3-26	296-304	diseases	abstract[17]	new[17]	_	_
3-27	305-309	with	_	_	_	_
3-28	310-317	various	abstract[18]	new[18]	_	_
3-29	318-324	levels	abstract[18]	new[18]	_	_
3-30	325-327	of	abstract[18]	new[18]	_	_
3-31	328-336	severity	abstract[18]|abstract	new[18]|new	_	_
3-32	337-338	.	_	_	_	_

#Text=Human coronavirus 229E ( HCoV-229E ) is a main cause of the common cold , while severe acute respiratory syndrome coronavirus ( SARS-CoV ) and Middle East respiratory syndrome coronavirus ( MERS-CoV ) cause severe respiratory disease that can be life-threatening to humans .
4-1	339-344	Human	abstract[21]	new[21]	coref	4-8[23_21]
4-2	345-356	coronavirus	plant|abstract[21]	new|new[21]	coref	4-17[26_0]
4-3	357-361	229E	abstract[21]	new[21]	_	_
4-4	362-363	(	_	_	_	_
4-5	364-373	HCoV-229E	object	new	_	_
4-6	374-375	)	_	_	_	_
4-7	376-378	is	_	_	_	_
4-8	379-380	a	abstract[23]	giv[23]	_	_
4-9	381-385	main	abstract[23]	giv[23]	_	_
4-10	386-391	cause	abstract[23]	giv[23]	_	_
4-11	392-394	of	abstract[23]	giv[23]	_	_
4-12	395-398	the	abstract[23]	giv[23]	_	_
4-13	399-405	common	abstract[23]	giv[23]	_	_
4-14	406-410	cold	abstract[23]	giv[23]	_	_
4-15	411-412	,	_	_	_	_
4-16	413-418	while	_	_	_	_
4-17	419-425	severe	plant[26]	giv[26]	coref	6-4[0_26]
4-18	426-431	acute	plant[26]	giv[26]	_	_
4-19	432-443	respiratory	abstract|plant[26]	new|giv[26]	_	_
4-20	444-452	syndrome	event|plant[26]	new|giv[26]	coref	4-29
4-21	453-464	coronavirus	plant[26]	giv[26]	_	_
4-22	465-466	(	_	_	_	_
4-23	467-475	SARS-CoV	abstract	new	coref	17-7
4-24	476-477	)	_	_	_	_
4-25	478-481	and	_	_	_	_
4-26	482-488	Middle	place[28]	new[28]	_	_
4-27	489-493	East	place[28]	new[28]	_	_
4-28	494-505	respiratory	_	_	_	_
4-29	506-514	syndrome	event	giv	_	_
4-30	515-526	coronavirus	_	_	_	_
4-31	527-528	(	_	_	_	_
4-32	529-537	MERS-CoV	abstract	new	coref	17-62
4-33	538-539	)	_	_	_	_
4-34	540-545	cause	_	_	_	_
4-35	546-552	severe	abstract[31]	new[31]	coref	8-18[65_31]
4-36	553-564	respiratory	abstract[31]	new[31]	_	_
4-37	565-572	disease	abstract[31]	new[31]	_	_
4-38	573-577	that	_	_	_	_
4-39	578-581	can	_	_	_	_
4-40	582-584	be	_	_	_	_
4-41	585-601	life-threatening	_	_	_	_
4-42	602-604	to	_	_	_	_
4-43	605-611	humans	person	new	_	_
4-44	612-613	.	_	_	_	_

#Text=However , some CoVs-like mouse hepatitis virus John Howard Mueller strain ( MHV-JHM ) infect oligodendrocytes , astrocytes and microglia and cause acute encephalomyelitis .
5-1	614-621	However	_	_	_	_
5-2	622-623	,	_	_	_	_
5-3	624-628	some	abstract[36]|person[37]	new[36]|new[37]	coref|coref	8-1[61_36]|8-1[61_36]
5-4	629-638	CoVs-like	abstract|abstract[36]|person[37]	new|new[36]|new[37]	_	_
5-5	639-644	mouse	animal|abstract[36]|person[37]	new|new[36]|new[37]	_	_
5-6	645-654	hepatitis	abstract|abstract[36]|person[37]	new|new[36]|new[37]	_	_
5-7	655-660	virus	abstract[36]|person[37]	new[36]|new[37]	_	_
5-8	661-665	John	abstract[36]|person[37]	new[36]|new[37]	_	_
5-9	666-672	Howard	abstract[36]|person[37]	new[36]|new[37]	_	_
5-10	673-680	Mueller	_	_	_	_
5-11	681-687	strain	_	_	_	_
5-12	688-689	(	_	_	_	_
5-13	690-697	MHV-JHM	abstract	new	_	_
5-14	698-699	)	_	_	_	_
5-15	700-706	infect	_	_	_	_
5-16	707-723	oligodendrocytes	person	new	_	_
5-17	724-725	,	_	_	_	_
5-18	726-736	astrocytes	object	new	_	_
5-19	737-740	and	_	_	_	_
5-20	741-750	microglia	object	new	_	_
5-21	751-754	and	_	_	_	_
5-22	755-760	cause	_	_	_	_
5-23	761-766	acute	abstract[42]	new[42]	_	_
5-24	767-784	encephalomyelitis	abstract[42]	new[42]	_	_
5-25	785-786	.	_	_	_	_

#Text=Additionally , human coronavirus OC43 ( HCoV-OC43 ) can also reach the central nervous system ( CNS ) by intranasal inoculation in BALB/c mice , which causes encephalitis .
6-1	787-799	Additionally	_	_	_	_
6-2	800-801	,	_	_	_	_
6-3	802-807	human	object[44]	new[44]	appos	6-7[0_44]
6-4	808-819	coronavirus	plant|object[44]	giv|new[44]	_	_
6-5	820-824	OC43	object[44]	new[44]	_	_
6-6	825-826	(	_	_	_	_
6-7	827-836	HCoV-OC43	object	giv	_	_
6-8	837-838	)	_	_	_	_
6-9	839-842	can	_	_	_	_
6-10	843-847	also	_	_	_	_
6-11	848-853	reach	_	_	_	_
6-12	854-857	the	place[46]	new[46]	_	_
6-13	858-865	central	place[46]	new[46]	_	_
6-14	866-873	nervous	place[46]	new[46]	_	_
6-15	874-880	system	place[46]	new[46]	_	_
6-16	881-882	(	_	_	_	_
6-17	883-886	CNS	place	new	_	_
6-18	887-888	)	_	_	_	_
6-19	889-891	by	_	_	_	_
6-20	892-902	intranasal	event[48]	new[48]	_	_
6-21	903-914	inoculation	event[48]	new[48]	_	_
6-22	915-917	in	event[48]	new[48]	_	_
6-23	918-924	BALB/c	event[48]|animal|animal[50]	new[48]|new|new[50]	_	_
6-24	925-929	mice	event[48]|animal[50]	new[48]|new[50]	_	_
6-25	930-931	,	_	_	_	_
6-26	932-937	which	_	_	_	_
6-27	938-944	causes	_	_	_	_
6-28	945-957	encephalitis	abstract	new	coref	7-22
6-29	958-959	.	_	_	_	_

#Text=The release of cytokines such as TNF-α , interleukin-1β ( IL-1β ) and interleukin-6 ( IL-6 ) is closely associated with encephalitis .
7-1	960-963	The	event[52]	new[52]	_	_
7-2	964-971	release	event[52]	new[52]	_	_
7-3	972-974	of	event[52]	new[52]	_	_
7-4	975-984	cytokines	event[52]|abstract[53]	new[52]|new[53]	_	_
7-5	985-989	such	event[52]|abstract[53]	new[52]|new[53]	_	_
7-6	990-992	as	event[52]|abstract[53]	new[52]|new[53]	_	_
7-7	993-998	TNF-α	event[52]|abstract[53]|abstract	new[52]|new[53]|new	_	_
7-8	999-1000	,	event[52]|abstract[53]	new[52]|new[53]	_	_
7-9	1001-1015	interleukin-1β	event[52]|abstract[53]|object	new[52]|new[53]|new	appos	7-11
7-10	1016-1017	(	event[52]|abstract[53]	new[52]|new[53]	_	_
7-11	1018-1023	IL-1β	event[52]|abstract[53]|object	new[52]|new[53]|giv	_	_
7-12	1024-1025	)	event[52]|abstract[53]	new[52]|new[53]	_	_
7-13	1026-1029	and	event[52]|abstract[53]	new[52]|new[53]	_	_
7-14	1030-1043	interleukin-6	event[52]|abstract[53]|abstract	new[52]|new[53]|new	appos	7-16
7-15	1044-1045	(	_	_	_	_
7-16	1046-1050	IL-6	abstract	giv	_	_
7-17	1051-1052	)	_	_	_	_
7-18	1053-1055	is	_	_	_	_
7-19	1056-1063	closely	_	_	_	_
7-20	1064-1074	associated	_	_	_	_
7-21	1075-1079	with	_	_	_	_
7-22	1080-1092	encephalitis	abstract	giv	_	_
7-23	1093-1094	.	_	_	_	_

#Text=Infectious bronchitis virus ( IBV ) belongs to the gamma-coronavirus group ( γ-CoV ) , which causes a highly contagious , acute viral respiratory disease of chickens that has caused great economic losses in the poultry industry .
8-1	1095-1105	Infectious	abstract[61]	giv[61]	appos	8-5[0_61]
8-2	1106-1116	bronchitis	person|abstract[61]	new|giv[61]	_	_
8-3	1117-1122	virus	abstract[61]	giv[61]	_	_
8-4	1123-1124	(	_	_	_	_
8-5	1125-1128	IBV	abstract	giv	coref	18-3
8-6	1129-1130	)	_	_	_	_
8-7	1131-1138	belongs	_	_	_	_
8-8	1139-1141	to	_	_	_	_
8-9	1142-1145	the	abstract[63]	new[63]	appos	8-13[0_63]
8-10	1146-1163	gamma-coronavirus	abstract[63]	new[63]	_	_
8-11	1164-1169	group	abstract[63]	new[63]	_	_
8-12	1170-1171	(	_	_	_	_
8-13	1172-1177	γ-CoV	abstract	giv	_	_
8-14	1178-1179	)	_	_	_	_
8-15	1180-1181	,	_	_	_	_
8-16	1182-1187	which	_	_	_	_
8-17	1188-1194	causes	_	_	_	_
8-18	1195-1196	a	abstract[65]	giv[65]	_	_
8-19	1197-1203	highly	abstract[65]	giv[65]	_	_
8-20	1204-1214	contagious	abstract[65]	giv[65]	_	_
8-21	1215-1216	,	abstract[65]	giv[65]	_	_
8-22	1217-1222	acute	abstract[65]	giv[65]	_	_
8-23	1223-1228	viral	abstract[65]	giv[65]	_	_
8-24	1229-1240	respiratory	abstract[65]	giv[65]	_	_
8-25	1241-1248	disease	abstract[65]	giv[65]	_	_
8-26	1249-1251	of	abstract[65]	giv[65]	_	_
8-27	1252-1260	chickens	abstract[65]|animal	giv[65]|new	coref	9-21
8-28	1261-1265	that	_	_	_	_
8-29	1266-1269	has	_	_	_	_
8-30	1270-1276	caused	_	_	_	_
8-31	1277-1282	great	abstract[67]	new[67]	_	_
8-32	1283-1291	economic	abstract[67]	new[67]	_	_
8-33	1292-1298	losses	abstract[67]	new[67]	_	_
8-34	1299-1301	in	abstract[67]	new[67]	_	_
8-35	1302-1305	the	abstract[67]|abstract[69]	new[67]|new[69]	ana	9-10[0_69]
8-36	1306-1313	poultry	abstract[67]|animal|abstract[69]	new[67]|new|new[69]	coref	24-17[203_0]
8-37	1314-1322	industry	abstract[67]|abstract[69]	new[67]|new[69]	_	_
8-38	1323-1324	.	_	_	_	_

#Text=At present , QX-type IBV is epidemic worldwide ; it can damage the respiratory , digestive and urogenital systems of chickens .
9-1	1325-1327	At	_	_	_	_
9-2	1328-1335	present	time	new	_	_
9-3	1336-1337	,	_	_	_	_
9-4	1338-1345	QX-type	place[71]	new[71]	coref	9-7[72_71]
9-5	1346-1349	IBV	place[71]	new[71]	_	_
9-6	1350-1352	is	_	_	_	_
9-7	1353-1361	epidemic	place[72]	giv[72]	coref	20-27[184_72]
9-8	1362-1371	worldwide	place[72]	giv[72]	_	_
9-9	1372-1373	;	_	_	_	_
9-10	1374-1376	it	abstract	giv	_	_
9-11	1377-1380	can	_	_	_	_
9-12	1381-1387	damage	_	_	_	_
9-13	1388-1391	the	object[74]	new[74]	_	_
9-14	1392-1403	respiratory	object[74]	new[74]	_	_
9-15	1404-1405	,	object[74]	new[74]	_	_
9-16	1406-1415	digestive	object[74]	new[74]	_	_
9-17	1416-1419	and	object[74]	new[74]	_	_
9-18	1420-1430	urogenital	object[74]	new[74]	_	_
9-19	1431-1438	systems	object[74]	new[74]	_	_
9-20	1439-1441	of	object[74]	new[74]	_	_
9-21	1442-1450	chickens	object[74]|animal	new[74]|giv	coref	10-11[78_0]
9-22	1451-1452	.	_	_	_	_

#Text=Besides , because of severe damage of respiratory mucosa , infected chickens are susceptible to secondary infection by mycoplasma , bacteria , or other pathogens causing high mortality .
10-1	1453-1460	Besides	_	_	_	_
10-2	1461-1462	,	_	_	_	_
10-3	1463-1470	because	_	_	_	_
10-4	1471-1473	of	_	_	_	_
10-5	1474-1480	severe	abstract[76]	new[76]	_	_
10-6	1481-1487	damage	abstract[76]	new[76]	_	_
10-7	1488-1490	of	abstract[76]	new[76]	_	_
10-8	1491-1502	respiratory	abstract[76]|object[77]	new[76]|new[77]	_	_
10-9	1503-1509	mucosa	abstract[76]|object[77]	new[76]|new[77]	_	_
10-10	1510-1511	,	_	_	_	_
10-11	1512-1520	infected	animal[78]	giv[78]	_	_
10-12	1521-1529	chickens	animal[78]	giv[78]	_	_
10-13	1530-1533	are	_	_	_	_
10-14	1534-1545	susceptible	_	_	_	_
10-15	1546-1548	to	_	_	_	_
10-16	1549-1558	secondary	abstract[79]	new[79]	_	_
10-17	1559-1568	infection	abstract[79]	new[79]	_	_
10-18	1569-1571	by	abstract[79]	new[79]	_	_
10-19	1572-1582	mycoplasma	abstract[79]|object	new[79]|new	_	_
10-20	1583-1584	,	abstract[79]	new[79]	_	_
10-21	1585-1593	bacteria	abstract[79]|animal	new[79]|new	_	_
10-22	1594-1595	,	abstract[79]	new[79]	_	_
10-23	1596-1598	or	abstract[79]	new[79]	_	_
10-24	1599-1604	other	abstract[79]|abstract[82]	new[79]|new[82]	_	_
10-25	1605-1614	pathogens	abstract[79]|abstract[82]	new[79]|new[82]	_	_
10-26	1615-1622	causing	_	_	_	_
10-27	1623-1627	high	abstract[83]	new[83]	_	_
10-28	1628-1637	mortality	abstract[83]	new[83]	_	_
10-29	1638-1639	.	_	_	_	_

#Text=All CoV virions encode a set of four structural proteins , namely ; spike glycoprotein ( S ) , small envelope protein ( E ) , membrane glycoprotein ( M ) and nucleocapsid proteins ( N ) .
11-1	1640-1643	All	animal[85]	new[85]	_	_
11-2	1644-1647	CoV	abstract|animal[85]	new|new[85]	_	_
11-3	1648-1655	virions	animal[85]	new[85]	_	_
11-4	1656-1662	encode	_	_	_	_
11-5	1663-1664	a	substance[86]	new[86]	_	_
11-6	1665-1668	set	substance[86]	new[86]	_	_
11-7	1669-1671	of	substance[86]	new[86]	_	_
11-8	1672-1676	four	substance[86]	new[86]	_	_
11-9	1677-1687	structural	substance[86]	new[86]	_	_
11-10	1688-1696	proteins	substance[86]	new[86]	_	_
11-11	1697-1698	,	_	_	_	_
11-12	1699-1705	namely	substance[88]	new[88]	coref	11-27[94_88]
11-13	1706-1707	;	substance[88]	new[88]	_	_
11-14	1708-1713	spike	object|substance[88]	new|new[88]	coref	15-20
11-15	1714-1726	glycoprotein	substance[88]	new[88]	_	_
11-16	1727-1728	(	_	_	_	_
11-17	1729-1730	S	abstract	new	coref	14-1
11-18	1731-1732	)	_	_	_	_
11-19	1733-1734	,	_	_	_	_
11-20	1735-1740	small	substance[91]	new[91]	coref	12-1[99_91]
11-21	1741-1749	envelope	object|substance[91]	new|new[91]	_	_
11-22	1750-1757	protein	substance[91]	new[91]	_	_
11-23	1758-1759	(	_	_	_	_
11-24	1760-1761	E	person	new	_	_
11-25	1762-1763	)	_	_	_	_
11-26	1764-1765	,	_	_	_	_
11-27	1766-1774	membrane	object|substance[94]	new|giv[94]	coref|coref	13-1[107_94]|13-1[107_94]
11-28	1775-1787	glycoprotein	substance[94]	giv[94]	_	_
11-29	1788-1789	(	_	_	_	_
11-30	1790-1791	M	abstract	new	_	_
11-31	1792-1793	)	_	_	_	_
11-32	1794-1797	and	_	_	_	_
11-33	1798-1810	nucleocapsid	abstract|substance[97]	new|new[97]	coref|coref	12-7[103_97]|12-7[103_97]
11-34	1811-1819	proteins	substance[97]	new[97]	_	_
11-35	1820-1821	(	_	_	_	_
11-36	1822-1823	N	person	new	_	_
11-37	1824-1825	)	_	_	_	_
11-38	1826-1827	.	_	_	_	_

#Text=S protein belongs to the class I fusion proteins , located at the surface of the virion .
12-1	1828-1829	S	substance[99]	giv[99]	coref	13-10[0_99]
12-2	1830-1837	protein	substance[99]	giv[99]	_	_
12-3	1838-1845	belongs	_	_	_	_
12-4	1846-1848	to	_	_	_	_
12-5	1849-1852	the	person[100]	new[100]	_	_
12-6	1853-1858	class	person[100]	new[100]	_	_
12-7	1859-1860	I	person|substance[103]	acc|giv[103]	_	_
12-8	1861-1867	fusion	abstract|substance[103]	new|giv[103]	coref	16-15
12-9	1868-1876	proteins	substance[103]	giv[103]	_	_
12-10	1877-1878	,	_	_	_	_
12-11	1879-1886	located	_	_	_	_
12-12	1887-1889	at	_	_	_	_
12-13	1890-1893	the	place[104]	new[104]	_	_
12-14	1894-1901	surface	place[104]	new[104]	_	_
12-15	1902-1904	of	place[104]	new[104]	_	_
12-16	1905-1908	the	place[104]|object[105]	new[104]|new[105]	_	_
12-17	1909-1915	virion	place[104]|object[105]	new[104]|new[105]	_	_
12-18	1916-1917	.	_	_	_	_

#Text=The trimeric S glycoprotein is a class I fusion protein and mediates attachment to the host receptor .
13-1	1918-1921	The	abstract[107]	giv[107]	coref	13-6[108_107]
13-2	1922-1930	trimeric	person[106]|abstract[107]	new[106]|giv[107]	_	_
13-3	1931-1932	S	person[106]|abstract[107]	new[106]|giv[107]	_	_
13-4	1933-1945	glycoprotein	abstract[107]	giv[107]	_	_
13-5	1946-1948	is	_	_	_	_
13-6	1949-1950	a	abstract[108]	giv[108]	_	_
13-7	1951-1956	class	abstract[108]	giv[108]	_	_
13-8	1957-1958	I	person	acc	_	_
13-9	1959-1965	fusion	_	_	_	_
13-10	1966-1973	protein	substance	giv	coref	15-9[123_0]
13-11	1974-1977	and	_	_	_	_
13-12	1978-1986	mediates	_	_	_	_
13-13	1987-1997	attachment	event	new	_	_
13-14	1998-2000	to	_	_	_	_
13-15	2001-2004	the	substance[113]	new[113]	_	_
13-16	2005-2009	host	person|substance[113]	new|new[113]	_	_
13-17	2010-2018	receptor	substance[113]	new[113]	_	_
13-18	2019-2020	.	_	_	_	_

#Text=S is typically cleaved by a host cell furin-like protease into two separate polypeptides named S1 and S2 .
14-1	2021-2022	S	person	giv	coref	15-10
14-2	2023-2025	is	_	_	_	_
14-3	2026-2035	typically	_	_	_	_
14-4	2036-2043	cleaved	_	_	_	_
14-5	2044-2046	by	_	_	_	_
14-6	2047-2048	a	animal[116]	new[116]	_	_
14-7	2049-2053	host	animal[116]	new[116]	_	_
14-8	2054-2058	cell	place|animal[116]	new|new[116]	coref	19-24
14-9	2059-2069	furin-like	animal[116]	new[116]	_	_
14-10	2070-2078	protease	animal[116]	new[116]	_	_
14-11	2079-2083	into	_	_	_	_
14-12	2084-2087	two	object[117]	new[117]	_	_
14-13	2088-2096	separate	object[117]	new[117]	_	_
14-14	2097-2109	polypeptides	object[117]	new[117]	_	_
14-15	2110-2115	named	_	_	_	_
14-16	2116-2118	S1	abstract	new	coref	15-1
14-17	2119-2122	and	_	_	_	_
14-18	2123-2125	S2	place	new	coref	15-14
14-19	2126-2127	.	_	_	_	_

#Text=S1 makes up the large receptor-binding domain of the S protein , while S2 forms the stalk of the spike molecule .
15-1	2128-2130	S1	abstract	giv	_	_
15-2	2131-2136	makes	_	_	_	_
15-3	2137-2139	up	_	_	_	_
15-4	2140-2143	the	abstract[121]	new[121]	_	_
15-5	2144-2149	large	abstract[121]	new[121]	_	_
15-6	2150-2166	receptor-binding	abstract[121]	new[121]	_	_
15-7	2167-2173	domain	abstract[121]	new[121]	_	_
15-8	2174-2176	of	abstract[121]	new[121]	_	_
15-9	2177-2180	the	abstract[121]|substance[123]	new[121]|giv[123]	coref	24-4[201_123]
15-10	2181-2182	S	abstract[121]|person|substance[123]	new[121]|giv|giv[123]	_	_
15-11	2183-2190	protein	abstract[121]|substance[123]	new[121]|giv[123]	_	_
15-12	2191-2192	,	_	_	_	_
15-13	2193-2198	while	_	_	_	_
15-14	2199-2201	S2	abstract	giv	coref	16-19
15-15	2202-2207	forms	_	_	_	_
15-16	2208-2211	the	plant[125]	new[125]	_	_
15-17	2212-2217	stalk	plant[125]	new[125]	_	_
15-18	2218-2220	of	plant[125]	new[125]	_	_
15-19	2221-2224	the	plant[125]|object[127]	new[125]|new[127]	_	_
15-20	2225-2230	spike	plant[125]|object|object[127]	new[125]|giv|new[127]	_	_
15-21	2231-2239	molecule	plant[125]|object[127]	new[125]|new[127]	_	_
15-22	2240-2241	.	_	_	_	_

#Text=There is an extra furin cleavage site ( furin-S2′ site ) upstream of the fusion peptide in the S2 subunit of some CoVs , which has been reported to influence the mechanism of invasion of host cells by CoVs .
16-1	2242-2247	There	_	_	_	_
16-2	2248-2250	is	_	_	_	_
16-3	2251-2253	an	organization[130]	new[130]	appos	16-9[131_130]
16-4	2254-2259	extra	organization[130]	new[130]	_	_
16-5	2260-2265	furin	person|organization[130]	new|new[130]	_	_
16-6	2266-2274	cleavage	person|organization[130]	new|new[130]	_	_
16-7	2275-2279	site	organization[130]	new[130]	_	_
16-8	2280-2281	(	_	_	_	_
16-9	2282-2291	furin-S2′	organization[131]	giv[131]	coref	17-28[150_131]
16-10	2292-2296	site	organization[131]	giv[131]	_	_
16-11	2297-2298	)	_	_	_	_
16-12	2299-2307	upstream	place[132]	new[132]	_	_
16-13	2308-2310	of	place[132]	new[132]	_	_
16-14	2311-2314	the	place[132]|substance[134]	new[132]|new[134]	_	_
16-15	2315-2321	fusion	place[132]|abstract|substance[134]	new[132]|giv|new[134]	_	_
16-16	2322-2329	peptide	place[132]|substance[134]	new[132]|new[134]	_	_
16-17	2330-2332	in	place[132]	new[132]	_	_
16-18	2333-2336	the	place[132]|abstract[136]	new[132]|new[136]	_	_
16-19	2337-2339	S2	place[132]|abstract|abstract[136]	new[132]|giv|new[136]	_	_
16-20	2340-2347	subunit	place[132]|abstract[136]	new[132]|new[136]	_	_
16-21	2348-2350	of	place[132]|abstract[136]	new[132]|new[136]	_	_
16-22	2351-2355	some	place[132]|abstract[136]|abstract[137]	new[132]|new[136]|giv[137]	coref	16-39[0_137]
16-23	2356-2360	CoVs	place[132]|abstract[136]|abstract[137]	new[132]|new[136]|giv[137]	_	_
16-24	2361-2362	,	_	_	_	_
16-25	2363-2368	which	_	_	_	_
16-26	2369-2372	has	_	_	_	_
16-27	2373-2377	been	_	_	_	_
16-28	2378-2386	reported	_	_	_	_
16-29	2387-2389	to	_	_	_	_
16-30	2390-2399	influence	_	_	_	_
16-31	2400-2403	the	abstract[138]	new[138]	_	_
16-32	2404-2413	mechanism	abstract[138]	new[138]	_	_
16-33	2414-2416	of	abstract[138]	new[138]	_	_
16-34	2417-2425	invasion	abstract[138]|event[139]	new[138]|new[139]	_	_
16-35	2426-2428	of	abstract[138]|event[139]	new[138]|new[139]	_	_
16-36	2429-2433	host	abstract[138]|event[139]|place[140]	new[138]|new[139]|giv[140]	coref	17-16[147_140]
16-37	2434-2439	cells	abstract[138]|event[139]|place[140]	new[138]|new[139]|giv[140]	_	_
16-38	2440-2442	by	abstract[138]|event[139]|place[140]	new[138]|new[139]|giv[140]	_	_
16-39	2443-2447	CoVs	abstract[138]|event[139]|place[140]|object	new[138]|new[139]|giv[140]|giv	_	_
16-40	2448-2449	.	_	_	_	_

#Text=When the original sequence PTKR/S of SARS-CoV was replaced with RRKR/S , SARS-CoV could invade susceptible cells while no longer relying on cathepsin L. Additionally , after the S2′ site mutated into the furin-S2′ site of the MHV-A59 strain , MHV can fuse with susceptible cells in the early endosome , but not lysosome , without requiring lysosomal enzymes such as MERS-CoV .
17-1	2450-2454	When	_	_	_	_
17-2	2455-2458	the	abstract[142]|abstract[143]	new[142]|new[143]	_	_
17-3	2459-2467	original	abstract[142]|abstract[143]	new[142]|new[143]	_	_
17-4	2468-2476	sequence	abstract[142]|abstract[143]	new[142]|new[143]	_	_
17-5	2477-2483	PTKR/S	abstract[143]	new[143]	_	_
17-6	2484-2486	of	abstract[143]	new[143]	_	_
17-7	2487-2495	SARS-CoV	abstract[143]|abstract	new[143]|giv	_	_
17-8	2496-2499	was	_	_	_	_
17-9	2500-2508	replaced	_	_	_	_
17-10	2509-2513	with	_	_	_	_
17-11	2514-2520	RRKR/S	abstract	new	_	_
17-12	2521-2522	,	_	_	_	_
17-13	2523-2531	SARS-CoV	person	new	_	_
17-14	2532-2537	could	_	_	_	_
17-15	2538-2544	invade	_	_	_	_
17-16	2545-2556	susceptible	place[147]	giv[147]	coref	17-45[156_147]
17-17	2557-2562	cells	place[147]	giv[147]	_	_
17-18	2563-2568	while	_	_	_	_
17-19	2569-2571	no	_	_	_	_
17-20	2572-2578	longer	_	_	_	_
17-21	2579-2586	relying	_	_	_	_
17-22	2587-2589	on	_	_	_	_
17-23	2590-2599	cathepsin	object[148]	new[148]	_	_
17-24	2600-2602	L.	object[148]	new[148]	_	_
17-25	2603-2615	Additionally	_	_	_	_
17-26	2616-2617	,	_	_	_	_
17-27	2618-2623	after	_	_	_	_
17-28	2624-2627	the	organization[150]	giv[150]	coref	17-33[152_150]
17-29	2628-2631	S2′	abstract|organization[150]	new|giv[150]	_	_
17-30	2632-2636	site	organization[150]	giv[150]	_	_
17-31	2637-2644	mutated	_	_	_	_
17-32	2645-2649	into	_	_	_	_
17-33	2650-2653	the	organization[152]	giv[152]	coref	18-5[164_152]
17-34	2654-2663	furin-S2′	abstract|organization[152]	new|giv[152]	coref	18-6
17-35	2664-2668	site	organization[152]	giv[152]	_	_
17-36	2669-2671	of	organization[152]	giv[152]	_	_
17-37	2672-2675	the	organization[152]|abstract[154]	giv[152]|new[154]	coref	18-15[168_154]
17-38	2676-2683	MHV-A59	organization[152]|abstract|abstract[154]	giv[152]|new|new[154]	_	_
17-39	2684-2690	strain	organization[152]|abstract[154]	giv[152]|new[154]	_	_
17-40	2691-2692	,	_	_	_	_
17-41	2693-2696	MHV	abstract	new	_	_
17-42	2697-2700	can	_	_	_	_
17-43	2701-2705	fuse	_	_	_	_
17-44	2706-2710	with	_	_	_	_
17-45	2711-2722	susceptible	place[156]	giv[156]	coref	19-32[177_156]
17-46	2723-2728	cells	place[156]	giv[156]	_	_
17-47	2729-2731	in	place[156]	giv[156]	_	_
17-48	2732-2735	the	place[156]|place[157]	giv[156]|new[157]	_	_
17-49	2736-2741	early	place[156]|place[157]	giv[156]|new[157]	_	_
17-50	2742-2750	endosome	place[156]|place[157]	giv[156]|new[157]	_	_
17-51	2751-2752	,	place[156]	giv[156]	_	_
17-52	2753-2756	but	place[156]	giv[156]	_	_
17-53	2757-2760	not	place[156]	giv[156]	_	_
17-54	2761-2769	lysosome	place[156]|abstract	giv[156]|new	_	_
17-55	2770-2771	,	_	_	_	_
17-56	2772-2779	without	_	_	_	_
17-57	2780-2789	requiring	_	_	_	_
17-58	2790-2799	lysosomal	abstract|abstract[160]	new|new[160]	_	_
17-59	2800-2807	enzymes	abstract[160]	new[160]	_	_
17-60	2808-2812	such	abstract[160]	new[160]	_	_
17-61	2813-2815	as	abstract[160]	new[160]	_	_
17-62	2816-2824	MERS-CoV	abstract[160]|abstract	new[160]|giv	_	_
17-63	2825-2826	.	_	_	_	_

#Text=As for IBV , the furin-S2′ site is a determinant of cellular adaptation of the IBV-Beaudette strain .
18-1	2827-2829	As	_	_	_	_
18-2	2830-2833	for	_	_	_	_
18-3	2834-2837	IBV	abstract	giv	coref	19-16
18-4	2838-2839	,	_	_	_	_
18-5	2840-2843	the	abstract[164]	giv[164]	coref	18-9[165_164]
18-6	2844-2853	furin-S2′	abstract|abstract[164]	giv|giv[164]	coref	21-11
18-7	2854-2858	site	abstract[164]	giv[164]	_	_
18-8	2859-2861	is	_	_	_	_
18-9	2862-2863	a	abstract[165]	giv[165]	coref	21-10[189_165]
18-10	2864-2875	determinant	abstract[165]	giv[165]	_	_
18-11	2876-2878	of	abstract[165]	giv[165]	_	_
18-12	2879-2887	cellular	abstract[165]|abstract[166]	giv[165]|new[166]	_	_
18-13	2888-2898	adaptation	abstract[165]|abstract[166]	giv[165]|new[166]	_	_
18-14	2899-2901	of	abstract[165]|abstract[166]	giv[165]|new[166]	_	_
18-15	2902-2905	the	abstract[165]|abstract[166]|abstract[168]	giv[165]|new[166]|giv[168]	coref	19-7[171_168]
18-16	2906-2919	IBV-Beaudette	abstract[165]|abstract[166]|person|abstract[168]	giv[165]|new[166]|new|giv[168]	coref	19-8
18-17	2920-2926	strain	abstract[165]|abstract[166]|abstract[168]	giv[165]|new[166]|giv[168]	_	_
18-18	2927-2928	.	_	_	_	_

#Text=If this motif is lacking , the IBV-Beaudette strain , which is normally the only IBV strain able to adapt to the Vero cell line , can no longer grow in these cells .
19-1	2929-2931	If	_	_	_	_
19-2	2932-2936	this	abstract[169]	new[169]	_	_
19-3	2937-2942	motif	abstract[169]	new[169]	_	_
19-4	2943-2945	is	_	_	_	_
19-5	2946-2953	lacking	_	_	_	_
19-6	2954-2955	,	_	_	_	_
19-7	2956-2959	the	abstract[171]	giv[171]	coref	19-14[173_171]
19-8	2960-2973	IBV-Beaudette	person|abstract[171]	giv|giv[171]	coref	20-14
19-9	2974-2980	strain	abstract[171]	giv[171]	_	_
19-10	2981-2982	,	_	_	_	_
19-11	2983-2988	which	_	_	_	_
19-12	2989-2991	is	_	_	_	_
19-13	2992-3000	normally	_	_	_	_
19-14	3001-3004	the	abstract[173]	giv[173]	coref	20-13[182_173]
19-15	3005-3009	only	abstract[173]	giv[173]	_	_
19-16	3010-3013	IBV	abstract|abstract[173]	giv|giv[173]	coref	20-5
19-17	3014-3020	strain	abstract[173]	giv[173]	_	_
19-18	3021-3025	able	_	_	_	_
19-19	3026-3028	to	_	_	_	_
19-20	3029-3034	adapt	_	_	_	_
19-21	3035-3037	to	_	_	_	_
19-22	3038-3041	the	object[176]	new[176]	_	_
19-23	3042-3046	Vero	person|object[176]	new|new[176]	_	_
19-24	3047-3051	cell	object|object[176]	giv|new[176]	coref	22-8
19-25	3052-3056	line	object[176]	new[176]	_	_
19-26	3057-3058	,	_	_	_	_
19-27	3059-3062	can	_	_	_	_
19-28	3063-3065	no	_	_	_	_
19-29	3066-3072	longer	_	_	_	_
19-30	3073-3077	grow	_	_	_	_
19-31	3078-3080	in	_	_	_	_
19-32	3081-3086	these	place[177]	giv[177]	_	_
19-33	3087-3092	cells	place[177]	giv[177]	_	_
19-34	3093-3094	.	_	_	_	_

#Text=Most basic research on IBV performed to date has been based on the IBV-Beaudette strain ; therefore , much remains unknown about the pathogenic mechanism of QX-type IBV .
20-1	3095-3099	Most	abstract[178]	new[178]	coref	24-19[0_178]
20-2	3100-3105	basic	abstract[178]	new[178]	_	_
20-3	3106-3114	research	abstract[178]	new[178]	_	_
20-4	3115-3117	on	abstract[178]	new[178]	_	_
20-5	3118-3121	IBV	abstract[178]|abstract	new[178]|giv	coref	21-22[192_0]
20-6	3122-3131	performed	_	_	_	_
20-7	3132-3134	to	_	_	_	_
20-8	3135-3139	date	time	new	_	_
20-9	3140-3143	has	_	_	_	_
20-10	3144-3148	been	_	_	_	_
20-11	3149-3154	based	_	_	_	_
20-12	3155-3157	on	_	_	_	_
20-13	3158-3161	the	abstract[182]	giv[182]	coref	24-21[206_182]
20-14	3162-3175	IBV-Beaudette	person|abstract[182]	giv|giv[182]	coref	24-22
20-15	3176-3182	strain	abstract[182]	giv[182]	_	_
20-16	3183-3184	;	_	_	_	_
20-17	3185-3194	therefore	_	_	_	_
20-18	3195-3196	,	_	_	_	_
20-19	3197-3201	much	_	_	_	_
20-20	3202-3209	remains	_	_	_	_
20-21	3210-3217	unknown	_	_	_	_
20-22	3218-3223	about	_	_	_	_
20-23	3224-3227	the	abstract[183]	new[183]	_	_
20-24	3228-3238	pathogenic	abstract[183]	new[183]	_	_
20-25	3239-3248	mechanism	abstract[183]	new[183]	_	_
20-26	3249-3251	of	abstract[183]	new[183]	_	_
20-27	3252-3259	QX-type	abstract[183]|substance[184]	new[183]|giv[184]	coref	21-7[187_184]
20-28	3260-3263	IBV	abstract[183]|substance[184]	new[183]|giv[184]	_	_
20-29	3264-3265	.	_	_	_	_

#Text=Here , we rescued a mutant QX-type IBV with the furin-S2′ site and compared the pathogenicity of the mutant IBV with its parental virus .
21-1	3266-3270	Here	_	_	_	_
21-2	3271-3272	,	_	_	_	_
21-3	3273-3275	we	person	acc	ana	22-1
21-4	3276-3283	rescued	_	_	_	_
21-5	3284-3285	a	person[186]	new[186]	_	_
21-6	3286-3292	mutant	person[186]	new[186]	_	_
21-7	3293-3300	QX-type	abstract[187]	giv[187]	coref	21-18[191_187]
21-8	3301-3304	IBV	abstract[187]	giv[187]	_	_
21-9	3305-3309	with	_	_	_	_
21-10	3310-3313	the	organization[189]	giv[189]	_	_
21-11	3314-3323	furin-S2′	abstract|organization[189]	giv|giv[189]	_	_
21-12	3324-3328	site	organization[189]	giv[189]	_	_
21-13	3329-3332	and	_	_	_	_
21-14	3333-3341	compared	_	_	_	_
21-15	3342-3345	the	abstract[190]	new[190]	_	_
21-16	3346-3359	pathogenicity	abstract[190]	new[190]	_	_
21-17	3360-3362	of	abstract[190]	new[190]	_	_
21-18	3363-3366	the	abstract[190]|abstract[191]	new[190]|giv[191]	coref	24-7[202_191]
21-19	3367-3373	mutant	abstract[190]|abstract[191]	new[190]|giv[191]	_	_
21-20	3374-3377	IBV	abstract[190]|abstract[191]	new[190]|giv[191]	_	_
21-21	3378-3382	with	abstract[190]|abstract[191]	new[190]|giv[191]	_	_
21-22	3383-3386	its	abstract[190]|abstract[191]|abstract[192]	new[190]|giv[191]|giv[192]	_	_
21-23	3387-3395	parental	abstract[190]|abstract[191]|abstract[192]	new[190]|giv[191]|giv[192]	_	_
21-24	3396-3401	virus	abstract[190]|abstract[191]|abstract[192]	new[190]|giv[191]|giv[192]	_	_
21-25	3402-3403	.	_	_	_	_

#Text=We also further investigated the tissue and cell tropism .
22-1	3404-3406	We	person	giv	ana	23-3
22-2	3407-3411	also	_	_	_	_
22-3	3412-3419	further	_	_	_	_
22-4	3420-3432	investigated	_	_	_	_
22-5	3433-3436	the	object[194]	new[194]	_	_
22-6	3437-3443	tissue	object[194]	new[194]	_	_
22-7	3444-3447	and	_	_	_	_
22-8	3448-3452	cell	place|abstract[196]	giv|new[196]	_	_
22-9	3453-3460	tropism	abstract[196]	new[196]	_	_
22-10	3461-3462	.	_	_	_	_

#Text=Finally , we clarified the biological significance with an immunoprotection experiment .
23-1	3463-3470	Finally	_	_	_	_
23-2	3471-3472	,	_	_	_	_
23-3	3473-3475	we	person	giv	_	_
23-4	3476-3485	clarified	_	_	_	_
23-5	3486-3489	the	abstract[198]	new[198]	_	_
23-6	3490-3500	biological	abstract[198]	new[198]	_	_
23-7	3501-3513	significance	abstract[198]	new[198]	_	_
23-8	3514-3518	with	abstract[198]	new[198]	_	_
23-9	3519-3521	an	abstract[198]|abstract[199]	new[198]|new[199]	_	_
23-10	3522-3538	immunoprotection	abstract[198]|abstract[199]	new[198]|new[199]	_	_
23-11	3539-3549	experiment	abstract[198]|abstract[199]	new[198]|new[199]	_	_
23-12	3550-3551	.	_	_	_	_

#Text=The function of S protein in QX-type IBV was demonstrated , which is more valuable for poultry than research about the IBV-Beaudette strain .
24-1	3552-3555	The	abstract[200]	new[200]	_	_
24-2	3556-3564	function	abstract[200]	new[200]	_	_
24-3	3565-3567	of	abstract[200]	new[200]	_	_
24-4	3568-3569	S	abstract[200]|substance[201]	new[200]|giv[201]	_	_
24-5	3570-3577	protein	abstract[200]|substance[201]	new[200]|giv[201]	_	_
24-6	3578-3580	in	abstract[200]|substance[201]	new[200]|giv[201]	_	_
24-7	3581-3588	QX-type	abstract[200]|substance[201]|abstract[202]	new[200]|giv[201]|giv[202]	_	_
24-8	3589-3592	IBV	abstract[200]|substance[201]|abstract[202]	new[200]|giv[201]|giv[202]	_	_
24-9	3593-3596	was	_	_	_	_
24-10	3597-3609	demonstrated	_	_	_	_
24-11	3610-3611	,	_	_	_	_
24-12	3612-3617	which	_	_	_	_
24-13	3618-3620	is	_	_	_	_
24-14	3621-3625	more	_	_	_	_
24-15	3626-3634	valuable	_	_	_	_
24-16	3635-3638	for	_	_	_	_
24-17	3639-3646	poultry	animal[203]	giv[203]	_	_
24-18	3647-3651	than	animal[203]	giv[203]	_	_
24-19	3652-3660	research	animal[203]|abstract	giv[203]|giv	_	_
24-20	3661-3666	about	animal[203]	giv[203]	_	_
24-21	3667-3670	the	animal[203]|abstract[206]	giv[203]|giv[206]	_	_
24-22	3671-3684	IBV-Beaudette	animal[203]|person|abstract[206]	giv[203]|giv|giv[206]	_	_
24-23	3685-3691	strain	animal[203]|abstract[206]	giv[203]|giv[206]	_	_
24-24	3692-3693	.	_	_	_	_
